{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:24:40Z","timestamp":1787635480815,"version":"build-2736575974"},"reference-count":108,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Several approaches have been investigated for preventing myopia progression in children and teenagers. Among them, topical atropine has shown promising results and it is being adopted in clinical practice more and more frequently. However, the optimal formulation and treatment algorithm are still to be determined. We discuss the pharmacokinetic, pharmacodynamic, clinical, and tolerability profile revealed first by the multicenter, randomized ATOM 1 and 2 trials and, more recently, by the LAMP Study. Results from these trials confirmed the efficacy of low-concentration atropine with a concentration-dependent response. Although atropine at 0.025% and 0.05% concentrations has shown the most encouraging results in large-scale studies, these formulations are not yet commonplace in worldwide clinical practice. Moreover, their rebound effect and the possibility of reaching a stabilization effect have not been fully investigated with real-life studies. Thus, further larger-scale studies should better characterize the clinical efficacy of atropine over longer follow-up periods, in order to define the optimal dosage and treatment regimen.<\/jats:p>","DOI":"10.3390\/pharmaceutics14050900","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T03:46:11Z","timestamp":1650512771000},"page":"900","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The Role of Atropine in Preventing Myopia Progression: An Update"],"prefix":"10.3390","volume":"14","author":[{"given":"Alberto","family":"Chierigo","sequence":"first","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, 16132 Genoa, Italy"},{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, 16126 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ferro Desideri","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, 16132 Genoa, Italy"},{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, 16126 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Enrico","family":"Traverso","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, 16132 Genoa, Italy"},{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, 16126 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9267","authenticated-orcid":false,"given":"Aldo","family":"Vagge","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, 16132 Genoa, Italy"},{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, 16126 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/519276a","article-title":"The myopia boom","volume":"519","author":"Dolgin","year":"2015","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10654-015-0098-2","article-title":"Ophthalmic epidemiology in Europe: The \u201cEuropean Eye Epidemiology\u201d (E3) consortium","volume":"31","author":"Delcourt","year":"2015","journal-title":"Eur. J. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1755-3768.1982.tb03031.x","article-title":"Ophthalmic changes from age of 10 to 18 years","volume":"60","author":"Fledelius","year":"2009","journal-title":"Acta Ophthalmol."},{"key":"ref_4","unstructured":"Kocur, I., Resnikoff, S., and Naidoo, K.S. (2022, March 21). Impact of Myopia Impact of Increasing and Myopia. No. July 2017, 2015. Available online: https:\/\/www.researchgate.net\/publication\/318216691_The_impact_of_myopia_and_high_myopia_Report_of_the_Joint_World_Health_Organization-Brien_Holden_Vision_Institute_Global_Scientific_Meeting_on_Myopia."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ophtha.2014.07.030","article-title":"Visual Consequences of Refractive Errors in the General Population","volume":"122","author":"Verhoeven","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Pellegrini, M., Vagge, A., Desideri, L.F.F., Bernabei, F., Triolo, G., Mastropasqua, R., Del Del Noce, C., Borrelli, E., Sacconi, R., and Iovino, C. (2020). Optical Coherence Tomography Angiography in Neurodegenerative Disorders. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061706"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ajo.2016.10.018","article-title":"Retinal Microvascular Network and Microcirculation Assessments in High Myopia","volume":"174","author":"Li","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"ref_8","first-page":"2654170","article-title":"Threshold Values of Myopic Anisometropia Causing Loss of Stereopsis","volume":"2019","year":"2019","journal-title":"J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy Comparison of 16 Interventions for Myopia Control in Children","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/aos.13403","article-title":"Time spent in outdoor activities in relation to myopia prevention and control: A meta-analysis and systematic review","volume":"95","author":"Xiong","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0197-2456(01)00156-8","article-title":"The Correction of Myopia Evaluation Trial (COMET): Design and General Baseline Characteristics","volume":"22","author":"Hyman","year":"2001","journal-title":"Control. Clin. Trials"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group (2011). Progressive-Addition Lenses versus Single-Vision Lenses for Slowing Progression of Myopia in Children with High Accommodative Lag and Near Esophoria. Investig. Ophthalmol. Vis. Sci., 52, 2749\u20132757.","DOI":"10.1167\/iovs.10-6631"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamaophthalmol.2013.7623","article-title":"Effect of Bifocal and Prismatic Bifocal Spectacles on Myopia Progression in Children","volume":"132","author":"Cheng","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","article-title":"Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: A 2-year randomised clinical trial","volume":"104","author":"Lam","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/OPX.0000000000000808","article-title":"Myopia Control with Bifocal Contact Lenses","volume":"93","author":"Aller","year":"2016","journal-title":"Optom. Vis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/00006324-196212000-00004","article-title":"World wide summary of contact lens techniques","volume":"39","author":"Jessen","year":"1962","journal-title":"Optom. Vis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0002-9394(03)00106-5","article-title":"A randomized trial of rigid gas permeable contact lenses to reduce progression of children\u2019s myopia","volume":"136","author":"Katz","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/OPX.0000000000001410","article-title":"A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control","volume":"96","author":"Chamberlain","year":"2019","journal-title":"Optom. Vis. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/02713683.2021.1878227","article-title":"Rebound Effect in the Misight Assessment Study Spain (Mass)","volume":"46","author":"Verdejo","year":"2021","journal-title":"Curr. Eye Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/bjophthalmol-2013-303914","article-title":"Defocus Incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: A 2-year randomised clinical trial","volume":"98","author":"Lam","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/02713680590907256","article-title":"The Longitudinal Orthokeratology Research in Children (LORIC) in Hong Kong: A Pilot Study on Refractive Changes and Myopic Control","volume":"30","author":"Cho","year":"2005","journal-title":"Curr. Eye Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1167\/iovs.12-10565","article-title":"Retardation of Myopia in Orthokeratology (ROMIO) Study: A 2-Year Randomized Clinical Trial","volume":"53","author":"Cho","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/01.ico.0000175412.13612.8a","article-title":"Infectious Keratitis Related to Overnight Orthokeratology","volume":"24","author":"Hsiao","year":"2005","journal-title":"Cornea"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.ajo.2014.08.026","article-title":"Orthokeratology-Associated Infectious Keratitis in a Tertiary Care Eye Hospital in Hong Kong","volume":"158","author":"Chan","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1442-9071.2002.00483.x","article-title":"Infectious keratitis in orthokeratology","volume":"30","author":"Hutchinson","year":"2002","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1475-1313.2006.00381.x","article-title":"Infectious keratitis related to orthokeratology","volume":"26","author":"Sun","year":"2006","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/01.ico.0000175410.28859.bd","article-title":"Acanthamoeba Keratitis During Orthokeratology","volume":"24","author":"Wilhelmus","year":"2005","journal-title":"Cornea"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/112067210901900120","article-title":"Orthokeratology Associated Microbial Keratitis","volume":"19","author":"Segev","year":"2009","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bjo.2008.151365","article-title":"Corneal reshaping and myopia progression","volume":"93","author":"Walline","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1167\/iovs.11-8005","article-title":"Myopia Control with Orthokeratology Contact Lenses in Spain: Refractive and Biometric Changes","volume":"53","author":"Gilmartin","year":"2012","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00417-018-3906-z","article-title":"MiSight Assessment Study Spain (MASS). A 2-year randomized clinical trial","volume":"256","author":"Valls","year":"2018","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaapos.2007.10.014","article-title":"Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2%pirenzepineophthalmicgelinchildrenwithmyopia","volume":"12","author":"Siatkowski","year":"2008","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12177-008-9013-3","article-title":"Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: A 36-month pilot study","volume":"1","author":"Trier","year":"2008","journal-title":"J. Ocul. Biol. Dis. Inform."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1007\/s10792-020-01535-w","article-title":"An update on pharmacological treatment options for amblyopia","volume":"40","author":"Vagge","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the Treatment of Childhood Myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_38","unstructured":"(2022, March 21). The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03140358."},{"key":"ref_39","unstructured":"(2022, March 21). Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03942419."},{"key":"ref_40","unstructured":"(2022, March 21). Topical 0.01% Atropine for the Control of Fast Progressing Myopia (Myopie-STOP), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04173780."},{"key":"ref_41","unstructured":"(1995). Exploring QSAR: Hydrophobic, Electronic, and Steric Constants, American Chemical Society."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sangster, J. (1994). LOGKOW Databank.","DOI":"10.1049\/cp:19940087"},{"key":"ref_43","first-page":"e238","article-title":"The penetration and distribution of topical atropine in animal ocular tissues","volume":"97","author":"Wang","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0014-4835(80)90047-0","article-title":"Interaction of drugs with ocular melanin in vitro","volume":"30","author":"Atlasik","year":"1980","journal-title":"Exp. Eye Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1034\/j.1600-0420.1999.770215.x","article-title":"Systemic bioavailability of ocularly applied 1% atropine eyedrops","volume":"77","author":"Kaila","year":"1999","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_46","first-page":"781","article-title":"The metabolism or atropine in man","volume":"38","author":"Hundt","year":"1986","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archopht.1959.04220010073007","article-title":"The Penetration of C14-Labeled Atropine into the Eye","volume":"62","author":"Janes","year":"1959","journal-title":"A.M.A. Arch. Ophthalmol."},{"key":"ref_48","unstructured":"(2021). Basic and Clinical Science Course, Section 02: Fundamentals and Principles of Ophthalmology, American Academy of Ophthalmology."},{"key":"ref_49","first-page":"727","article-title":"Antagonist binding profiles of five cloned human muscarinic receptor subtypes","volume":"256","author":"Wess","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_50","first-page":"469","article-title":"Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells","volume":"35","author":"Buckley","year":"1989","journal-title":"Mol. Pharmacol."},{"key":"ref_51","first-page":"1434","article-title":"Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation","volume":"38","author":"Gil","year":"1997","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_52","first-page":"2633","article-title":"Characterization of muscarinic receptors in human lens cells by pharmacologic and molecular techniques","volume":"41","author":"Collison","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S0952523811000204","article-title":"The influences of metabotropic receptor activation on cellular signaling and synaptic function in amacrine cells","volume":"29","author":"Gleason","year":"2011","journal-title":"Vis. Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0006-8993(88)91291-7","article-title":"Human retinal pigment epithelial cells possess muscarinic receptors coupled to calcium mobilization","volume":"446","author":"Friedman","year":"1988","journal-title":"Brain Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ruan, Y., Patzak, A., Pfeiffer, N., and Gericke, A. (2021). Muscarinic Acetylcholine Receptors in the Retina\u2014Therapeutic Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094989"},{"key":"ref_56","first-page":"1277","article-title":"Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation","volume":"15","author":"Barathi","year":"2009","journal-title":"Mol. Vis."},{"key":"ref_57","first-page":"2217","article-title":"Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes","volume":"39","author":"Lind","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0014-4835(91)90027-C","article-title":"Muscarinic antagonist effects on experimental chick myopia","volume":"52","author":"Stone","year":"1991","journal-title":"Exp. Eye Res."},{"key":"ref_59","first-page":"1146","article-title":"Muscarinic cholinergic receptor (M2) plays a crucial role in the development of myopia in mice","volume":"6","author":"Barathi","year":"2013","journal-title":"Dis. Model. Mech."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1475-1313.2011.00841.x","article-title":"The M4 muscarinic antagonist MT-3 inhibits myopia in chick: Evidence for site of action","volume":"31","author":"McBrien","year":"2011","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0006-8993(98)00188-7","article-title":"Cholinergic amacrine cells are not required for the progression and atropine-mediated suppression of form-deprivation myopia","volume":"794","author":"Fischer","year":"1998","journal-title":"Brain Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1073\/pnas.86.2.704","article-title":"Retinal dopamine and form-deprivation myopia","volume":"86","author":"Stone","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.preteyeres.2017.06.003","article-title":"Dopamine signaling and myopia development: What are the key challenges","volume":"61","author":"Zhou","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cne.902100108","article-title":"Dopaminergic neurons in the human retina","volume":"210","author":"Frederick","year":"1982","journal-title":"J. Comp. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/j.1460-9568.1996.tb01192.x","article-title":"Immunohistochemical Localization of Dopamine D Receptors in Rat Retina","volume":"8","author":"Veruki","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0304-3940(97)00783-0","article-title":"Molecular identification of a dopamine D1b receptor in bovine retinal pigment epithelium","volume":"237","author":"Gibert","year":"1997","journal-title":"Neurosci. Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0006-8993(95)00700-Z","article-title":"Localization of putative dopamine D2-like receptors in the chick retina, using in situ hybridization and immunocytochemistry","volume":"695","author":"Rohrer","year":"1995","journal-title":"Brain Res."},{"key":"ref_68","first-page":"3038","article-title":"C57BL\/6 mouse eyes treated by dopamine D1 receptor agonist and antagonist during form deprivation: An opposite effect on axial length and refractive development","volume":"55","author":"Zhou","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1167\/iovs.16-20402","article-title":"Bright Light Suppresses Form-Deprivation Myopia Development With Activation of Dopamine D1 Receptor Signaling in the ON Pathway in Retina","volume":"58","author":"Chen","year":"2017","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E003","DOI":"10.1017\/S0952523816000195","article-title":"Intravitreally-administered dopamine D2-like (and D4), but not D1-like, receptor agonists reduce form-deprivation myopia in tree shrews","volume":"34","author":"Ward","year":"2017","journal-title":"Vis. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1167\/iovs.17-21574","article-title":"Dopamine Receptor Subtypes Mediate Opposing Effects on Form Deprivation Myopia in Pigmented Guinea Pigs","volume":"59","author":"Zhang","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1167\/iovs.13-13211","article-title":"Activation of Dopamine D2 Receptor Is Critical for the Development of Form-Deprivation Myopia in the C57BL\/6 Mouse","volume":"55","author":"Huang","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_73","first-page":"1674","article-title":"Effects of apomorphine, a dopamine receptor agonist, on ocular refraction and axial elongation in a primate model of myopia","volume":"32","author":"Iuvone","year":"1991","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1167\/iovs.14-14294","article-title":"Effects of Dopaminergic Agents on Progression of Naturally Occurring Myopia in Albino Guinea Pigs (Cavia porcellus)","volume":"55","author":"Jiang","year":"2014","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00006324-200402000-00012","article-title":"Inhibitory Effects of Apomorphine and Atropine and Their Combination on Myopia in Chicks","volume":"81","author":"Schmid","year":"2004","journal-title":"Optom. Vis. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0952523800171184","article-title":"Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick","volume":"17","author":"Schwahn","year":"2000","journal-title":"Vis. Neurosci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1167\/iovs.17-22562","article-title":"Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro","volume":"59","author":"Carr","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41598-016-0002-7","article-title":"Nitric Oxide (NO) Mediates the Inhibition of Form-Deprivation Myopia by Atropine in Chicks","volume":"6","author":"Carr","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/OPX.0000000000000041","article-title":"Nitric Oxide Synthase Inhibitors Prevent the Growth-Inhibiting Effects of Quinpirole","volume":"90","author":"Nickla","year":"2013","journal-title":"Optom. Vis. Sci."},{"key":"ref_80","first-page":"205","article-title":"Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism","volume":"34","author":"McBrien","year":"1993","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Cristaldi, M., Olivieri, M., Pezzino, S., Spampinato, G., Lupo, G., Anfuso, C.D., and Rusciano, D. (2020). Atropine Differentially Modulates ECM Production by Ocular Fibroblasts, and Its Ocular Surface Toxicity Is Blunted by Colostrum. Biomedicines, 8.","DOI":"10.3390\/biomedicines8040078"},{"key":"ref_82","first-page":"15","article-title":"Effects of Atropine Treatment on Choroidal Thickness in Myopic Children","volume":"61","author":"Ye","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"34936","DOI":"10.1038\/srep34936","article-title":"The effect of topical atropine on the choroidal thickness of healthy children","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101348","DOI":"10.1016\/j.clae.2020.06.006","article-title":"Short-term effects of atropine combined with orthokeratology (ACO) on choroidal thickness","volume":"44","author":"Zhao","year":"2020","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8528315","DOI":"10.1155\/2018\/8528315","article-title":"Effect of Atropine Eye Drops on Choroidal Thinning Induced by Hyperopic Retinal Defocus","volume":"2018","author":"Chiang","year":"2018","journal-title":"J. Ophthalmol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0161-6420(79)35455-0","article-title":"The Effect of Atropine on Myopia","volume":"86","author":"Bedrossian","year":"1979","journal-title":"Ophthalmology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0161-6420(84)34138-0","article-title":"The Treatment of Myopia with Atropine and Bifocals","volume":"91","author":"Brodstein","year":"1984","journal-title":"Ophthalmology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jop.1997.13.61","article-title":"The Effectiveness of 0.5% Atropine in Controlling High Myopia in Children","volume":"13","author":"Chou","year":"1997","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of Atropine","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%","volume":"157","author":"Chia","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2","volume":"123","author":"Chia","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.1999.15.85","article-title":"Effects of Different Concentrations of Atropine on Controlling Myopia in Myopic Children","volume":"15","author":"Shih","year":"1999","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/eye.2016.78","article-title":"Effectiveness study of atropine for progressive myopia in Europeans","volume":"30","author":"Polling","year":"2016","journal-title":"Eye"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia","volume":"31","author":"Clark","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40123-019-0194-6","article-title":"A Pilot Study on the Efficacy and Safety of 0.01% Atropine in German Schoolchildren with Progressive Myopia","volume":"8","author":"Joachimsen","year":"2019","journal-title":"Ophthalmol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The Long-Term Results of Using Low-Concentration Atropine Eye Drops for Controlling Myopia Progression in Schoolchildren","volume":"27","author":"Wu","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7150\/ijms.39365","article-title":"Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children","volume":"17","author":"Zhu","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"La atropina superdiluida al 0.01% frena el aumento de miop\u00eda en ni\u00f1os-adolescentes. Un estudio a largo plazo 5 a\u00f1os de evoluci\u00f3n: Seguridad y eficacia","volume":"93","year":"2018","journal-title":"Arch. Soc. Espa\u00f1ola Oftalmol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) Study","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: The good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1167\/iovs.16-20903","article-title":"The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells","volume":"58","author":"Datta","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/cxo.12967","article-title":"Which low-dose atropine for myopia control?","volume":"103","author":"Khanal","year":"2020","journal-title":"Clin. Exp. Optom."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2018","journal-title":"Eye"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"M184","DOI":"10.1167\/iovs.18-25977","article-title":"IMI\u2014Clinical Management Guidelines Report","volume":"60","author":"Gifford","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Pellegrini, M., Senni, C., Bernabei, F., Cicero, A.F.G., Vagge, A., Maestri, A., Scorcia, V., and Giannaccare, G. (2020). The Role of Nutrition and Nutritional Supplements in Ocular Surface Diseases. Nutrients, 12.","DOI":"10.3390\/nu12040952"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamaophthalmol.2013.7376","article-title":"Secondary Analyses of the Effects of Lutein\/Zeaxanthin on Age-Related Macular Degeneration Progression","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Kim, H., Seo, J.S., Yoo, W.-S., Kim, G.-N., Kim, R.B., Chae, J.E., Chung, I., Seo, S.-W., and Kim, S.J. (2020). Factors associated with myopia in Korean children: Korea National Health and nutrition examination survey 2016\u20132017 (KNHANES VII). BMC Ophthalmol., 20.","DOI":"10.1186\/s12886-020-1316-6"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/5\/900\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:57:42Z","timestamp":1760137062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/5\/900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":108,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["pharmaceutics14050900"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14050900","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]}}}